Pfizer Inc. (PFE)

In the past six months, Pfizer has experienced renewed investor optimism following clinical trial wins in oncology and a regulatory vaccine approval in Singapore. Pfizer reached a drug pricing agreement with the White House in October 2025, lowering prices on several medications in exchange for a three-year exemption on specific tariffs. In July 2025, Pfizer underwent a corporate restructuring that included the departure of its chief corporate affairs officer, Sally Susman, and four of her deputies. Pfizer reported its quarterly earnings on August 5, 2025, with an EPS of $0.78, beating analysts' consensus estimates of $0.58. As of October 24, 2025, Pfizer's stock price was $24.76, down 14.21% from October 28, 2024.

Demand seasonality exists for some of Pfizer Inc.'s products, particularly its vaccines, such as the COVID-19 vaccine. The company's financial models account for a decline in this seasonal vaccine demand. Specialized tools are available to analyze Pfizer's historical price patterns and percentage win rates by month.

Pfizer Inc. is a multinational pharmaceutical and biotechnology corporation headquartered in New York City, founded in 1849. It operates within the Pharmaceutical and Biotechnology sectors, focusing on the discovery, development, manufacture, marketing, sale, and distribution of medicines and vaccines globally. The company develops and produces medications and vaccines across various therapeutic areas, including immunology, oncology, cardiology, endocrinology, and neurology. Some of Pfizer's major products by 2024 sales include Eliquis, Prevnar, Paxlovid, Vyndaqel, Comirnaty, and Ibrance. Beyond prescription drugs and vaccines, Pfizer also produces well-known over-the-counter products such as Advil, Nexium, Centrum, ChapStick, Robitussin, and Preparation H.

Pfizer has a significant global presence, serving customers worldwide. The company's headquarters are located in New York City, USA. Pfizer operates manufacturing units in numerous countries, including Belgium, Germany, India, Ireland, Italy, Japan, Singapore, and the United States. In 2024, 61% of Pfizer's revenues were generated from the United States, 4% from China, and the remaining 35% from other international markets.

Pfizer's brand reputation experienced shifts, with a boost during the COVID-19 pandemic followed by a return to pre-COVID levels by early 2023. In July 2025, Pfizer announced a corporate restructuring that involved the departure of Sally Susman. Pfizer's ongoing clinical studies can positively influence its reputation as a leader in complex disease research. In October 2024, activist investor Starboard Value publicly criticized Pfizer for R&D inefficiencies and overpaid acquisitions.

Pfizer Inc.'s ownership structure is a mix of institutional, retail, and individual investors. The largest institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. The top individual/insider shareholders in Pfizer are Albert Bourla (Chairman and CEO), Mikael Dolstenand, and Douglas Lanker. Retail investors hold a substantial portion, around 34.47%, of Pfizer's stock.